VYLIQ: A DEEP LOOK INTO THE EMERGING TREATMENT

Vyliq, formerly known as relecabtagene autotempa, represents a significant step in the management of relapsed or refractory aggressive large B-cell lymphoma (LBCL). This unique therapy utilizes a modified CAR-T cell product specifically engineered to the B-cell target CD22. Clinical research have